Biocon Completes BBL Acquisition, Allots Equity Shares Worth ₹694 Crore
Biocon Limited completed the acquisition of 26,19,17,480 equity shares of Biocon Biologics Limited (BBL) and allotted 17,12,79,553 equity shares on a preferential basis on January 05, 2026. The company also acquired additional BBL shares from Mylan for USD 200 million. Biocon now holds ~94% of BBL.
The acquisition of a material subsidiary and the subsequent equity allotment are strategically important for Biocon, impacting its corporate structure and ownership of Biocon Biologics.
The company successfully completed a significant acquisition and a preferential share allotment, increasing its stake in a key subsidiary and consolidating its business structure.
Biocon Limited has announced the completion of its acquisition of equity shares in its unlisted material subsidiary, Biocon Biologics Limited (BBL). Following the extraordinary general meeting held on December 31, 2025, the company, on January 05, 2026, finalized the acquisition of 26,19,17,480 equity shares of BBL from various allottees including Mylan Inc., Serum Institute Life Sciences Private Limited, Tata Capital Growth Fund II, and Activ Pine LLP. Concurrently, Biocon issued and allotted 17,12,79,553 equity shares of its own on a preferential basis to these same allottees as consideration for the acquisition. The issue price for these shares was ₹405.78 per equity share. This preferential allotment results in the allottees holding a combined 11.36% stake in Biocon Limited.
The company also completed the acquisition of an additional 7,18,34,691 equity shares of BBL from Mylan for a cash consideration of USD 200 million (approximately ₹1,660 crore, assuming an exchange rate of 83 INR/USD). This is part of a larger planned acquisition of 14,36,69,382 equity shares from Mylan for USD 400 million. Post these transactions, Biocon holds approximately 94% of the paid-up equity share capital of BBL on a fully diluted basis.
The preferential issue and allotment involved shares valued at approximately ₹694 crore (17,12,79,553 shares * ₹405.78/share). The meeting of the Fund Raising Committee, which approved these allotments, commenced at 09:15 PM and concluded at 09:30 PM on January 05, 2026.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.